Stem Cells Spin SA SCS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 46.99
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1 and Velvetyna.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1
- Website
- http://stemcellsspin.com.pl
Valuation
Metric
|
SCS
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.62 |
Price/Sales | 46.99 |
Price/Cash Flow | 15.75 |
Price/Earnings
No chart available
Financial Strength
Metric
|
SCS
|
---|---|
Quick Ratio | 0.44 |
Current Ratio | 4.61 |
Interest Coverage | −105.28 |
Quick Ratio
SCS
Profitability
Metric
|
SCS
|
---|---|
Return on Assets (Normalized) | 1.04% |
Return on Equity (Normalized) | 2.02% |
Return on Invested Capital (Normalized) | 1.98% |
Return on Assets
SCS
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ffmwfhwb | Qpq | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Yvhpwmjl | Qndfvmn | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ymzrhdghk | Szgzr | $105.6 Bil | |
MRNA
| Moderna Inc | Pfykwshj | Jsrk | $40.8 Bil | |
ARGX
| argenx SE ADR | Dvgpmccz | Hzd | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Hwglpxn | Ygbs | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fmxhdxxhx | Jztzwyt | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zpqxcfwq | Yprfgfg | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lvmfyvwnb | Rvrlzjr | $13.6 Bil | |
INCY
| Incyte Corp | Zxdjgchj | Lxbghq | $12.8 Bil |